Abstract Body

Antiretroviral therapy (ART) initiation during acute HIV infection (AHI) limits HIV reservoirs, enhances reservoir decay, restricts viral genetic diversification and may facilitate post-ART control. Identifying and treating persons with AHI is highly desirable but logistically challenging. We describe the performance of new AHI diagnostic criteria for an ongoing multi-national study of ART initiation during AHI.

ACTG 5354 enrolls adults during AHI at 29 sites in the Americas, Africa, and Southeast Asia. Participants must meet one of the following criteria: (A) detectable HIV RNA and non-reactive HIV antibody; (B) detectable HIV RNA or reactive antibody and negative/indeterminate Western blot (WB) or Geenius; (C) negative HIV RNA or antibody within 90 days and reactive antibody, WB (p31-), or Geenius (p31-) within 7 days; (D) ARCHITECT or GSCOMBO antigen/antibody (Ag/Ab) combo signal-to-cutoff ratio (S/CO) ≥10 and non-reactive HIV antibody. Participants start ART at enrollment. HIV infection and Fiebig stage at ART initiation are subsequently confirmed by centralized testing that includes HIV RNA, ARCHITECT Ag/Ab, Bio-Rad HIV-1/2 Ab (IgM sensitive), and Geenius HIV-1/2 lateral flow antibody assay.

From January 2017 through August 2019, 174 were enrolled and completed centralized confirmatory testing. Their median age was 27 (interquartile range 23-38) years and 29 (17%) were female. ART was started by 154 (89%) on the day of enrollment and 20 (11%) the next day, mostly with study-provided elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine (n=136, 78%). AHI was confirmed in 167 (96%) participants after centralized testing and varied in Fiebig stage according to the AHI criteria used (Figure Panel A). Three participants with locally detectable HIV RNA had no evidence of infection on centralized testing, discontinued ART and were withdrawn. Four others were in Fiebig VI, not AHI, at enrollment. Centralized ARCHITECT S/CO ≥10 combined with nonreactive or indeterminate HIV antibody on the Geenius assay correctly identified 87 of 106 (82%) Fiebig II-IV AHI cases (Figure Panel B).

Novel efficient AHI criteria incorporating ARCHITECT S/CO into diagnostic algorithms facilitated rapid ART initiation pending confirmation. False-positive diagnoses of AHI were rare. These new criteria may facilitate AHI diagnosis, staging, and immediate ART initiation in research studies and clinical practice.